It’s time that we open our collective eyes to the realities of most breast cancer screening programs: they fail to engage the majority of women.
Breast cancer screening programs that rely solely upon one the widespread availability of a single, poorly adopted modality, fail women. Without widespread availability and adoption, there’s no significant impact upon the health of populations.
To be very clear: mammograms have saved hundreds of thousands of lives and we are in no way “anti-mammogram.” Instead, we are “pro-reality,” and that reality is that the adoption of mammography by women in most countries is very poor.
It’s time for and additional modality, one that can be made easily available and that women will adopt. That modality is Bexa.
DCIS - "stage 0"
unscreened but treated invasive
breast cancer - stages I-IV
Committing to offer only mammograms doesn’t make humanitarian sense, clinical sense, or financial sense. What does make sense is to offer an additonal modality - Bexa - that can engage the women that won’t or can’t have mammograms.
The majority of invasive breast cancers present as an abnormal mass. For abnormal masses, Bexa has a high sensitivity and low need for follow-on studies. Learn more about the detailed clinical performance of Bexa here.
Even low-cost Bexa examinations represent new and profitable revenues for your practice, facility or system. Most of the “marketplace of women at risk,” and the opportunity they represent, is lost to physicians who only offer historic technologies. Bexa represents an opportunity to “do good,” while adding a new service line and new business.